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Channelopathieschannels) contribute to a wide variety of physiological functions, especially in the
cardiovascular and nervous systems. Recent studies using knock-out mouse models have been instrumental
in documenting further the role of T-channels in sleep, heartbeat, pain and epilepsy. Importantly, several
novel aspects of the regulation of these channels have been identiﬁed over the last few years, providing new
insights into their physiological and pathophysiological roles. Here, we review recent evidence supporting
that the Cav3 subunits of T-channels are modulated by endogenous ligands such as anandamide, zinc, redox
and oxidizing agents, as well as G-protein and protein kinases pathways. The study of T-channel mutations
associated with childhood absence epilepsy has also revealed new aspects of Cav3 subunit trafﬁcking.
Collectively, these ﬁndings identify novel regulatory mechanisms involved in the ﬁne tuning of T-channel
expression and activity, and offer new directions for the design of novel therapeutic strategies targeting these
channels.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionFor almost two decades, until their cloning in the late 99s, T-type
calcium channels (T-channels) were considered as an electrophysio-
logical curiosity, being activated and open close to the membrane's
resting potential (also designated LVA for low-voltage activated) in
most excitable cells, especially in neurons [1,2]. The presence of T-type
calcium currents (T-current) in a wide variety of cells, as well as in
early development and disease models, resulted in many hypotheses
regarding the role of T-channels being made. However, validating
them has proven problematic due to the lack of selective T-channel
blockers. The identiﬁcation of three genes: CACNA1G, CACNA1H and
CACNA1I, coding for the T-channels Cav3.1/α1G, Cav3.2/α1H and
Cav3.3/α1I, respectively (see Table 1; reviewed in [3–5]), was a
signiﬁcant landmark in the ﬁeld, offering novel technical approaches
to tackle the properties and signiﬁcance of T-channels in physiology
and pathology [6,7]. These last 10 years, therefore, many aspects have
been identiﬁed, validating former observations and providing novel
exciting paradigms regarding the properties and roles of T-channels.
2. T-type calcium channels: molecular basis of their diversity
Three genes code for T-channels (Table 1) and analysis of the
various corresponding cDNAs clearly indicate that many splicell rights reserved.variants exists for the three Cav3.1, Cav3.2 and Cav3.3 subunits. Of
importance, the cloned Cav3 subunits express well in heterologous
systems (Xenopus oocytes, mammalian cells…), which allows detailed
electrophysiological studies of the Cav3.1, Cav3.2 and Cav3.3 subunits.
The three recombinant Cav3 subunits generate T-type/low-voltage
activated calcium currents (T-current) with distinct biophysical
properties [8] and the Cav3.1 and Cav3.2 subunits generate T-currents
that are highly reminiscent to those recorded in native cells (neurons,
cardiac cells…). As mentioned above, alternative splicing notably
enhances the diversity of T-channel isoforms [9–11] and there is
growing evidence for signiﬁcant differences in the electrophysiologi-
cal properties of these splice variants of a given Cav3 subunit,
especially the Cav3.1 subunit isoforms [5,12,13]. Overall, this bulk of
data clearly supports that the molecular and functional diversity of T-
channels in native cells can primarily arise from the expression of a
wide variety of splice variants of the three Cav3 subunits. Interestingly,
one should note that it is almost exclusively the intracellular regions of
the Cav3 subunits that are subject to alternative splicing, especially the
loops between the transmembrane domains and the C-terminal
region [5]. It is therefore tempting to hypothesize that the modulation
of T-channels, including secondmessenger pathways, is also impacted
by alternative splicing, although this has yet to be experimentally
supported.
Because they are phylogenetically related, T-channels should be
compared to other voltage-activated calciumchannels, i.e. the L-N-P/Q-
and R-types that belong to the high-voltage-activated (HVA) family.
One important feature of HVA channels is their heteromultimeric
Table 1
T-type calcium channel genes and related diseases
Channel
type
Gene
name
Chromosome
loc.
SNPs/mutations in human diseases Ref.
Cav3.1 CACNA1G 17q22 Juvenile myoclonic epilepsy (JME) [50]
Cav3.2 CACNA1H 16p13.3 Childhood absence epilepsy (CAE) and
other idiopathic generalized epilepsies
(IGE)
[47,49]
Autism spectrum disorder (ASD) [56]
Cav3.3 CACNA1I 22q13 –
The three genes encoding the Cav3 subunits of T-type calcium channels, as well as their
chromosome localization, are listed here. Additional information regarding these genes
can be found elsewhere, especially at OMIM or HUGO websites (http://www.ncbi.nlm.
nih.gov/omim/ and http://www.genenames.org/). T-channels are susceptibility genes
for epilepsy. Many variants for CACNA1H are found in epileptic patients, especially for
CAE (see text).
Fig. 1. A schematic representation of the recently identiﬁed regulatory pathways for
Cav3 channels, especially for Cav3.2 channels (see text for details and references).
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prominent targeting and biophysical roles in the channel's activity
[14,15]. To date, evidence for an interaction between HVA ancillary
subunits and T-channels is sparse but data supporting a regulatory role
for some of the β, α2δ and γ subunits of HVA channels have been
reported [16,17]. Because Cav3 channels display properties fairly well
matching those of native T-channels, it seems reasonable to speculate
that T-channel auxiliary subunit(s), if any, would play a more discrete
functional role compared to that of the β, α2δ and γ subunits of HVA
channels. Puriﬁcation and biochemical characterization of HVA
channels had also beneﬁted from the existence of selective ligands
(i.e. dihydropyridines and toxins), as well as a considerably large panel
of subunit-speciﬁc antibodies. This is not yet the case for the Cav3
subunits, preventing, until now, the characterization of T-channel
complexes from native tissues [18].
3. New insights into the modulation of T-type calcium channels
Modulation of Cav3/T-channels has only recently been substan-
tiated. We previously reported that the extensive study of T-channel
modulation in native tissues did not provide support for the
existence of generic modulation pathways of T-channels [19].
Using functional expression of recombinant Cav3 channels, many
recent studies have now validated the idea that T-channels can be
modulated by various endogenous ligands as well as by second
messenger pathways. One of the ﬁrst descriptions of T-channels
being regulated by an endogenous ligand was made with the
endocannabinoid anandamide [20], a bioactive lipid also known to
be active on CB receptors, TRPV1 channels and two-pore K+
channels [21]. Anandamide, as well as arachidonic acid, other N-
acyl ethanolamides (AEA) and polyunsaturated fatty acids (PUFA)
[22,23], inhibit Cav3 channels in the micromolar range through a
membrane-delimited – possibly direct – interaction. Among the
other signalling molecules that potently affect T-channels, zinc has
been focused on. Zinc somehow acts as a neurotransmitter as it is
released from the presynaptic vesicles of glutamatergic neurons
(sometimes described as “gluzinergic” neurons) and free zinc mod-
ulates many membrane receptors, transporters and channels [24].
Interestingly zinc differentially regulates the three Cav3 channel
isotypes: it preferentially inhibits Cav3.2 channels with an IC50 in the
submicromolar range (∼0.8 μM), which is 100 and 200-fold lower than
what is observed for Cav3.1 and Cav3.3 channels, respectively [25]. In
addition, zinc signiﬁcantly slows the deactivation kinetics of the Cav3.3/
T-current, i.e. the tail current, which consequently causes an enhanced
calcium entry through Cav3.3 channels [25]. In these experimental
conditions, it appears that zinc operates as a mixed blocker/opener of
Cav3.3 channels. Interestingly, Todorovic et al. recently reported that the
reducing agent L-cysteine, which can upregulate T-current in nocicep-
tive neurons [26], likely produces its effect through chelation of freezinc ions that mediate a tonic block of Cav3.2 channels [27]. Zinc pro-
duces its blocking effect on Cav3.2 channels through binding to an
extracellular histidine (His191) residue localized in the S3–S4 segment
of domain I of Cav3.2 channel [27]. His191 was originally identiﬁed as a
critical determinant of the nickel block of Cav3.2 channels [28]. In
addition, the oxidizing agent, ascorbate, also produces Cav3.2 channel
inhibition through the metal-catalyzed oxidation of this speciﬁc His191
[29], further demonstrating that this amino-acid is an important
checkpoint in the modulation of Cav3.2 channel activity (Fig. 1).
Many G-protein coupled receptors (GPCRs) are potential mod-
ulators of T-channels in a large variety of cells types [19] and several
aspects of GPCR modulation of Cav3 channels have recently been
documented. Using a heterologous system, it was shown that the
activation of the muscarinic M1 receptor could result in a selective
G protein-induced inhibition of Cav3.3 channels through a Gαq/α11
pathway [30]. By contrast, activation of corticotropin releasing factor
receptor 1 (CRFR1), which selectively inhibits Cav3.2 channels, likely
mediates its effect through a cholera toxin sensitive, Gβγ-dependent
pathway [31]. Notably, it was shown in a previous study that Cav3.2
inhibition by the G protein β2 and γ (Gβ2γ) subunits can occur via a
direct interaction between the Gβ2γ subunits and the channel's
intracellular linker between domains II and III (II–III loop) [32,33].
Several other recent studies have shown that Cav3/T-channels can
be also modulated by second messengers and protein kinase
pathways. Welsby et al. provided evidence that CamKII selectively
promotes the activation of Cav3.2 channels [34]. A series of Cav3.1/
Cav3.2 chimera was used to pinpoint the role of the II–III loop of
Cav3.2 and, ultimately, the Serine 1198 residue was found to be
instrumental in the CamKII regulation of Cav3.2 channels as it is
dynamically phosphorylated in vivo [35]. Other Serine/threonine
kinases as well as protein kinases A and C (PKA and PKC) have also
been shown to enhance activity of the three recombinant Cav3
subunits of T-channels, both in Xenopus oocytes [36,37] and in
mammalian cells at physiological temperature [38]. The speciﬁc
residue(s) involved in these serine/threonine kinase modulations
have not been identiﬁed yet, although they are known to require the
II–III loop, both for Cav3.2 in the case of PKA [37] and for Cav3.1 in
the case of PKC modulation [36]. By contrast, activation of Rho
kinase/ROCK via lysophosphatidic (LPA) receptor activation results
in an inhibition of Cav3.1 and Cav3.3 currents and involves two
clusters of serine and threonine residues of the II–III loop of Cav3.1
[39]. Overall, this wealth of data strikingly identiﬁes the intracellular
II–III loop of Cav3 channels as an important determinant for channel
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1). Forthcoming studies should aimat further identifying the relevance
of these recently described mechanisms converging at the II–III loop
locus, reminiscent of a crosstalk mechanism identiﬁed for Cav2
channels [40], as well as evaluating whether or not the other
intracellular domains of Cav3 channels play a role in the GPCR-
mediated regulation of Cav3 channels. Through these upcoming
studies, many of the “orphan”modulations of native T-channels, such
as an ATP-dependent potentiation of T-channels in thalamocortical
neurons [41,42], should be puzzled out.
4. T-type calcium channels and related channelopathies
4.1. Childhood absence epilepsy (CAE)
T-channels play an important role in neuron excitability, especially
in the thalamocortical loop, and therefore are considered as suscept-
ibility genes in epilepsy. The description of an increase in T-channel
activity in thalamic neurons of animal models of absence epilepsy was
provided a long time ago with the GAERS rat [43], as well as more
recently using the mouse lines tottering, lethargic, stargazer and colo-
boma [44,45] and the WAG/rij rat [46]. In humans, mutations in the
CACNA1H (Cav3.2) and CACNA1G (Cav3.1) genes have been identiﬁed
in epilepsy patients [47–50] (see Table 1). Originally, Chen et al. [47]
found twelve single nucleotide polymorphisms (SNPs)/missense
mutations in CACNA1H associated with childhood absence epilepsy
(CAE). Heron et al. [48,49] have extended the number of SNPs in
CACNA1H linked to idiopathic generalized epilepsy (IGE) and
proposed that these variants contribute to patients' susceptibility to
epilepsy but are not alone sufﬁcient to cause generalized epilepsy.
Electrophysiological characterization of the corresponding Cav3.1 and
Cav3.2 mutants in heterologous expression systems has revealed only
discrete biophysical alterations that are unlike to support a signiﬁcant
gain of channel activity [50–52]. Looking at the distribution of the
CAE mutations in the Cav3.2 protein, it appears that many of these
mutations are present in the linker between domains I and II (I–II
loop) of the protein. This suggests a functional role of this intra-
cellular region. Indeed, the I–II loop regulates expression of the
Cav3.2 subunit at the plasma membrane [53]. While Cav3.2 channels
are markedly retained in intracellular compartments (only ∼12% at
the plasma membrane), it appears that deletion in the I–II loop
signiﬁcantly enhances surface expression of Cav3.2 channels: +300%
[53]. This is in contrast with a higher surface expression of both
Cav3.1 (∼25%) and Cav3.3 channels (∼30%), in which deletion in the
I–II loop produces mild changes in surface expression (+40% and
−30%, respectively) [54]. The determinants involved in Cav3.2
trafﬁcking are preferentially contained in the central region of the
I–II loop. Along with these data, it was shown that all the CAE
mutants of Cav3.2 exhibit signiﬁcant increase in surface expression
[53]. Finally these experiments also provide evidence that the three
Cav3 subunits have in common a proximal domain of the I–II loop –
adjacent to the domain I – that contributes to the gating properties,
which has been described as a gating brake [54,55]. Altogether,
these studies indicate that a more comprehensive view of the
structure–function relationships of Cav3 channels can be gained
from the study of disease-related mutations.
4.2. Autism spectrum disorder (ASD)
Recently, several missense mutations linked to autism spectrum
disorder (ASD) were found within CACNA1H [56]. All these
mutations signiﬁcantly altered Cav3.2 channel activity, causing a
positive shift in activation properties and a reduction in conduc-
tance. Mutations in Cav3.2 channels may not be the only impair-
ment causing the ASD phenotype: autism is a complex,
behaviourally deﬁned, static disorder of the immature brain.Mutations in CACNA1H may act as modiﬁers of its phenotypic
expression. Interestingly, it should be stressed that one third of ASD
patients suffer from epilepsy [56]. Based on the critical role of T-
channels in neuronal development and excitability [57], it is
reasonable to consider that mutations in CACNA1H may affect
proper neuronal function, especially during neurogenesis [58].
5. Modulation of T-type calcium channel expression: more than a
disease marker?
Analysis of the density of T-currents strongly suggests that their
expression is highly modulated during development as well as in
several experimental pathological situations [57]. Only a few
examples will be reviewed here. In a rat model of post myocardial
infarction, de novo expression of T-channels is observed in ventricular
myocytes [59] and is reminiscent of the embryonic pattern of Cav3
subunit expression in heart [60]. In addition, angiotensin II and
endothelin-1 are able to induce ventricular hypertrophy and T-
channel expression [61,62]. Similarly, up-regulation of T-channel
expression occurs in several neurological diseases. Along with the
description linking T-channels and genetic absence epilepsy (see
above), there is evidence for an increase in T-channel expression in
CA1 pyramidal neurons in a rat model of temporal lobe epilepsy [63].
Also, along with recent data indicating that T-channels play a crucial
role in tuning sensory neuron excitability and serve as ampliﬁers in
peripheral pain transmission [64,65], Jagodic et al. [66] have described
an upregulation of T-channel expression in a subpopulation of DRG
sensory neurons in rats with painful diabetic neuropathy.
An important challenge will now be to resolve whether de novo, or
up-regulation, of T-channel expression is adaptative or maladaptative
of these various disease states. Regarding the implication of T-
channels in the cardiac hypertrophy phenotype: T-channel activity
could represent a deleterious calcium entry mechanism affecting
calcium handling and contractile properties in hypertrophied cardiac
myocytes. This is partly supported by pharmacological studies
showing that hypertrophy can be attenuated in the presence of T-
channel blockers [67]. Conversely, it may be worth considering that
calcium entry through T-channels, which plays an important role in
developing cardiac myocytes, could contribute to counterbalance the
deleterious effect of hypertrophy. Indeed, a recent study revealed
that mice overexpressing Cav3.1 channels in the heart, under the
control of the α-myosin heavy chain promoter, did not develop a
pathological cardiac phenotype, i.e. hypertrophy or arrhythmogenic
sudden death [68]. This data, which also indicates that Cav3.1 T-
channels are ineffective in triggering excitation–contraction cou-
pling, suggests that overexpression of T-channels does not induce
cardiac dysfunction. Additional experiments are required to further
identify the role of T-channels in hypertrophic or post-infarction
remodelled heart. The recent development of knock-out animals for
Cav3.1 and Cav3.2 may offer new opportunities to address these
important questions. Similar hypotheses and objectives can be
formulated regarding the up-regulation of T-channels in CA1 and
DRG neurons in temporal lobe epilepsy and diabetic neuropathy,
respectively.
Because T-channels are present in many transformed cell lines,
such as neuroblastoma, retinoblastoma, glioma cells and thyroid
carcinoma cells, it is hypothesized that a link exists between these
channels and cancer [67]. Interestingly it appears that in one given
tissue, T-channel expression can be modulated in opposite ways in
cancer cells. The Cav3.2 subunit of T-channels is overexpressed in
neuroendocrine prostate LNCaP cells [69], as well as in primary cells
obtained after surgical removal of prostate cancer biopsies [70]. An
increase in Cav3.2 activity may account for enhanced autocrine/
paracrine secretions in neuroendocrine prostate cancer, i.e. prostatic
acid phosphatase (PAP) synthesis and secretion [70]. In contrast, the
gene coding for Cav3.1 is hypermethylated in several cancer types,
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Cav3.1 expression.
6. Pharmacology of T-type calcium channels
For years the “ion channel community” has been waiting for
selective blockers for T-channels and it seems that this recent post-
cloning era is full of promises. Many reviews have described various
organic molecules, members of many drug classes: dihydropyridines,
succinimide derivatives, diphenylbutylpiperidine derivatives, benzo-
diazepines, anesthetics … that are currently used to treat a variety of
neuronal and cardiovascular diseases and are inhibitors of T-channels.
Unfortunately, most of these classical T-channel blockers do not allow
discrimination between T-channels and other VGCC-related signals
and none are selective enough for T-channels [72–74]. There is a great
need for selective blockers in the T-channel toolkit as many new
hypotheses regarding the pathophysiological role of T-channels are
emerging. One can now anticipate that a new generation of more
selective T-channel blockers will soon be available [75–77] and,
hopefully, these new T-channel blockers may also have appeal in
clinical use as they may hold therapeutic interest in treating severe
pain and epilepsy [77] and possibly lowering heart rate and decreasing
blood pressure.
7. Perspectives and conclusion
Many new insights into T-channel properties and roles have been
gained this last decade. Ten years after the cloning of the Cav3
subunits, knock out animals for Cav3.1 and Cav3.2 have been pro-
duced and will be helpful to further explore the involvement of
T-channels in a wide variety of physiological and pathophysiological
states. In Cav3.1−/− mice that show no signiﬁcant histological and
physiological abnormalities, the complete lack of T-currents in
thalamocortical relay neurons [78] and in sinoatrial node cells [79]
has further documented the major role of T-channels in neuronal
burst ﬁring and cardiac pacemaker activity. In Cav3.2−/− mice, the
role of this channel isoform in nociception was conﬁrmed [65].
Interestingly, Cav3.2−/− mice show signiﬁcant vasoconstriction of
coronary arteries. This phenotype may be related to altered
endothelial nitric oxide (NO)-mediated vasodilation that is observed
in Cav3.2−/− arteries, and/or to altered activity of the large con-
ductance calcium-activated potassium (BKCa) channels that were
found associated to the Cav3.2 protein [80]. Knock out mice are
undoubtedly useful animal models to probe the physiological and
pathophysiological roles of T-channels. However, constitutive inacti-
vation of these genes in animals may lead to compensatory
phenomenons that mask the precise involvement of either Cav3.1
or Cav3.2 activity. For example, discrepancies in the neuropathic pain
phenotype between Cav3.2−/− mice and animals that undergo
antisense knock-down [64,65] suggest that compensatory effects in
knock-out animals alleviate their response to hyperalgesia. Unfortu-
nately, no report of the functional consequences of Cav3.3 knock-out
has been published to date.
Are T-channels multimeric complexes? Besides data regarding
interaction of the Cav3.2 proteinwith the BKCa channel [80], G-protein
β2γ2 subunits [32], as well as the attempts to identify whether the
HVA auxiliary subunits physically associate with Cav3 subunits [16,17],
it is expected that Cav3 proteins form larger complexes with currently
unknown partners. In the coming years, such partners should be
identiﬁed.
Are T-channels relevant drug targets? Recent efforts have led to the
identiﬁcation of more selective T-channel blockers [77] and it is
expected that T-channel antagonists are potential therapeutic agents,
especially for the treatment of neurological diseases [72–74]. With the
recent identiﬁcation of isoform-speciﬁc properties, the need to design
ligands selective for a given T-channel subtype has emerged. Thechallenge will then be to deﬁne whether speciﬁc T-channel isoforms/
variants can be selectively targeted for therapeutic intervention.
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